Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative ECX with or without bevacizumab in operable oesophagogastric adenocarcinoma
2006-000811-12Phase 2Terminated
- Sponsor
- MRC Clinical Trials Unit at UCL
- Start
- Jan 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab, lapatinib, epirubicin, cisplatin and capecitabine in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma, esophageal adenocarcinoma (EAC) and 1 more (3 arms), sponsored by MRC Clinical Trials Unit at UCL. Primary endpoints: Overall survival and Safety. Started Jan 2007; status: terminated.
02
Drugs
bevacizumablapatinibepirubicincisplatincapecitabine
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on 2006-000811-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000811-12.